Front Pharmacol. 2018 Feb 12;9:98. doi: 10.3389/fphar.2018.00098. eCollection 2018.
Frontiers in pharmacology
Steffen K Meurer, Ralf Weiskirchen
PMID: 29483873 PMCID: PMC5816342 DOI: 10.3389/fphar.2018.00098
We have identified a phenomenon occurring in the usage of proposed "specific" Mitogen-activated protein kinase (MAPK) inhibitors. We found that especially inhibitors of p38 potentiate the activation of other MAPKs in various cell types. This finding will have tremendous impact on the interpretation of all former studies using MAPK inhibitors.
Keywords: PD98059; PDGF-BB; SB203580; SP600125; UO126; inhibitors; mitogen-activated protein kinases; signal transduction